Cáncer de esófago

+ -Text Size

Otros recursos y referencias TEMAS

Referencias: guía detallada del cáncer de esófago

American Cancer Society. Cancer Facts and Figures 2013. Atlanta, Ga: American Cancer Society; 2013.

American Joint Committee on Cancer. AJCC Cancer Staging Manual. 7th ed. New York, NY: Springer; 2010:103-111.

Burmeister BH, Smithers BM, Gebski V, et al. Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase III trial. Lancet Oncol. 2005;6:659–668.

Chak A, Chen Y, Vengoechea J, et al. Variation in age at cancer diagnosis in familial versus nonfamilial Barrett's esophagus. Cancer Epidemiol Biomarkers Prev. 2012 Feb;21(2):376-83. Epub 2011 Dec 16.

Enzinger PC, Mayer RJ. Esophageal cancer. New Engl J Med. 2003; 349:2241-2252.

Howlader N, Noone AM, Krapcho M, et al (eds). SEER Cancer Statistics Review, 1975-2009 (Vintage 2009 Populations), National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2009_pops09/, based on November 2011 SEER data submission, posted to the SEER web site, April 2012.

Kantor ED, Onstad L, Blount PL, Reid BJ, Vaughan TL. Use of statin medications and risk of esophageal adenocarcinoma in persons with Barrett's esophagus. Cancer Epidemiol Biomarkers Prev. 2012 Mar;21(3):456-61. Epub 2012 Jan 12.

Kastelein F, Spaander MC, Biermann K, Steyerberg EW, Kuipers EJ, Bruno MJ; Probar-study Group. Nonsteroidal anti-inflammatory drugs and statins have chemopreventative effects in patients with Barrett's esophagus. Gastroenterology. 2011 Dec;141(6):2000-8; quiz e13-4. Epub 2011 Aug 28.

Kleinberg LR, Brock MV, Jagannath SB, Forastiere AA. Cancer of the esophagus. In: Abeloff MD, Armitage JO, Lichter AS, Niederhuber JE. Kastan MB, McKenna WG, eds. Abeloff's Clinical Oncology. 4th ed. Philadelphia, Pa: Elsevier; 2008:1399-1429.

Koshy M, Esiashvilli N, Landry JC, et al. Multiple management modalities in esophageal cancer. Oncologist. 2004;9:137–146 and 147–159.

National Cancer Institute. Physician Data Query (PDQ). Esophageal Cancer Treatment. 7/13/2012. Accessed at www.cancer.gov/cancertopics/pdq/treatment/esophageal/HealthProfessional on October 4, 2012.

National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Esophageal and Esophagogastric Junction Cancers. V.2.2012. Accessed at www.nccn.org on October 1. 2012.

Nguyen DM, Richardson P, El-Serag HB. Medications (NSAIDs, statins, proton pump inhibitors) and the risk of esophageal adenocarcinoma in patients with Barrett's esophagus. Gastroenterology. 2010 Jun;138(7):2260-6. Epub 2010 Feb 23.

Posner MC, Minsky B, Ilson DH. Cancer of the esophagus. In: DeVita VT, Hellman S, Rosenberg SA, eds. DeVita, Hellman, and Rosenberg's Cancer: Principles and Practice of Oncology. 9th ed. Philadelphia, Pa: Lippincott-Williams & Wilkins; 2011:887-923.

Shaheen NJ, Sharma P, Overholt BF, et al. Radiofrequency ablation in Barrett's esophagus with dysplasia. N Engl J Med. 2009;360:2277-2288.

Souza RF, Spechler SJ. Concepts in the prevention of adenocarcinoma of the distal esophagus and proximal stomach. CA Cancer J Clin. 2005;55:334–351.

The Esophageal Adenocarcinoma Genetics Consortium; The Wellcome Trust Case Control Consortium 2, Su Z, Gay LJ, Strange A, et al. Common variants at the MHC locus and at chromosome 16q24.1 predispose to Barrett's esophagus. Nat Genet. 2012 Sep 9;44(10):1131-1136.

van Hagen P, Hulshof MC, van Lanschot JJ, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012 May 31;366(22):2074-84.


Fecha de última actualización: 02/14/2013
Fecha de último cambio o revisión: 02/14/2013